Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
1.540
-0.025 (-1.60%)
At close: Aug 28, 2026, 4:00 PM EDT
1.550
+0.010 (0.65%)
After-hours: Aug 28, 2026, 7:30 PM EDT

Cadrenal Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
8.829.356.753.552.52
Research & Development
2.834.14.214.080.43
Operating Expenses
11.6513.4610.967.632.95
Operating Income
-11.65-13.46-10.96-7.63-2.95
Interest Expense
----0.02-0.12
Interest & Investment Income
0.110.220.310.250
Other Non Operating Income (Expenses)
----0.22-4.26
EBT Excluding Unusual Items
-11.54-13.24-10.65-7.62-7.32
Other Unusual Items
----0.74-
Pretax Income
-11.54-13.24-10.65-8.36-7.32
Net Income
-11.54-13.24-10.65-8.36-7.32
Net Income to Common
-11.54-13.24-10.65-8.36-7.32
Net Income Growth
-----
Shares Outstanding (Basic)
22111
Shares Outstanding (Diluted)
22111
Shares Change
44.92%63.48%35.59%70.99%-
EPS (Basic)
-4.86-6.64-8.73-9.29-13.92
EPS (Diluted)
-4.86-6.64-8.73-9.29-13.92
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-10.16-12.61-7.36-3.53-1.32
Free Cash Flow Per Share
-4.28-6.32-6.04-3.93-2.50
EBITDA
-11.65-13.45-10.96-7.63-2.95
D&A For EBITDA
00.01000
EBIT
-11.65-13.46-10.96-7.63-2.95
SEC Filings: 10-K · 10-Q